Compare OMH & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMH | AYTU |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 27.4M |
| IPO Year | 2022 | 2015 |
| Metric | OMH | AYTU |
|---|---|---|
| Price | $0.80 | $2.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 17.4K | ★ 50.9K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,632,080.00 |
| Revenue This Year | $28.40 | N/A |
| Revenue Next Year | $23.07 | $43.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $0.59 | $1.46 |
| 52 Week High | $3.25 | $3.07 |
| Indicator | OMH | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 32.26 | 34.14 |
| Support Level | $0.75 | $2.15 |
| Resistance Level | $1.38 | $2.30 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 11.72 | 28.91 |
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.